{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:45:51Z","timestamp":1772063151551,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.lungcan.2014.10.010","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T06:43:57Z","timestamp":1414133037000},"page":"339-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer"],"prefix":"10.1016","volume":"86","clinical-trial-number":[{"clinical-trial-number":"umin000004568","registry":"10.18810\/umin-japan"}],"author":[{"given":"T.","family":"Naito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2014.10.010_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"10.1016\/j.lungcan.2014.10.010_bib0010","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lungcan.2014.10.010_bib0015","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2014.10.010_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.lungcan.2014.10.010_bib0025","first-page":"4004","article-title":"Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats","volume":"53","author":"Shirasaka","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2014.10.010_bib0030","series-title":"Proceeding of the 2012 ASCO Annual Meeting J Clin Oncol","article-title":"Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701)","author":"Katakami","year":"2012"},{"issue":"36","key":"10.1016\/j.lungcan.2014.10.010_bib0035","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2010.31.0326","article-title":"Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan Oncology Group Study","volume":"28","author":"Okamoto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lungcan.2014.10.010_bib0040","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/JTO.0b013e3182307e5a","article-title":"S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706)","volume":"6","author":"Ichinose","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2014.10.010_bib0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.bjc.6605152","article-title":"Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer","volume":"101","author":"Ohyanagi","year":"2009","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2014.10.010_bib0050","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/JTO.0b013e3182103b51","article-title":"Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer","volume":"6","author":"Govindan","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2014.10.010_bib0055","first-page":"85","article-title":"Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer","volume":"74","author":"Shiroyama","year":"2011","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2014.10.010_bib0060","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00280-009-0981-1","article-title":"A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer","volume":"64","author":"Totani","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.lungcan.2014.10.010_bib0065","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00280-011-1795-5","article-title":"Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer","volume":"69","author":"Wada","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9 PT 1","key":"10.1016\/j.lungcan.2014.10.010_bib0070","first-page":"3288","article-title":"Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil","volume":"41","author":"Evans","year":"1981","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.lungcan.2014.10.010_bib0075","first-page":"144","article-title":"Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice","volume":"41","author":"Houghton","year":"1981","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.lungcan.2014.10.010_bib0080","first-page":"393","article-title":"Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: evidence from a xenograft model of folate-depleted mice","volume":"2","author":"Tsukioka","year":"2009","journal-title":"Mol Med Rep"},{"issue":"4","key":"10.1016\/j.lungcan.2014.10.010_bib0085","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/annonc\/mdp371","article-title":"Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer","volume":"21","author":"Koizumi","year":"2010","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.lungcan.2014.10.010_bib0090","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2004.03.104","article-title":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis","volume":"22","author":"Thirion","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2014.10.010_bib0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2014.10.010_bib0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2014.10.010_bib0105","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00280-013-2090-4","article-title":"A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer","volume":"71","author":"Sasaki","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.lungcan.2014.10.010_bib0110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00280-013-2368-6","article-title":"Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer","volume":"73","author":"Sudo","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2014.10.010_bib0115","series-title":"Proceeding of the 2013 Gastrointestinal Cancers Symposium J Clin Oncol","article-title":"Phase II study of S-1 plus leucovorin (a new 1-week treatment regimen followed by a 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China","author":"Denda","year":"2012"},{"issue":"13","key":"10.1016\/j.lungcan.2014.10.010_bib0120","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","article-title":"Potential regional differences for the tolerability profiles of fluoropyrimidines","volume":"26","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.lungcan.2014.10.010_bib0125","first-page":"2116","article-title":"Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.lungcan.2014.10.010_bib0130","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO.2000.18.14.2772","article-title":"Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors","volume":"18","author":"van Groeningen","year":"2000","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.lungcan.2014.10.010_bib0135","first-page":"2253","article-title":"[Phase I study of S-1, S-1 Study Group]","volume":"24","author":"Taguchi","year":"1997","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214004449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214004449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T15:44:05Z","timestamp":1565970245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500214004449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0169500214004449"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.10.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}